Sapovirus in Adults in Rehabilitation Center, Upper Austria

minimum of 10 d. Patients should be retested for ongoing viral secretion every 5 d and negative results confi rmed with a follow-up sample after 48 h. Classic virus isolation in addition to molecular methods may also identify potentially infectious patients. Prophylactic neuraminidase inhibitor use in such patients also needs to be addressed. Resistance is more likely with the reduced prophylactic dose of oseltamivir and is more likely to be a problem in immunocompromised patients. Zanamivir is now the drug of choice for prophylaxis for such patients, although some experts propose no prophylaxis and instead early treatment after symptom onset (9). Immunocompromised patients are more likely to shed virus for prolonged periods and are more likely to develop oseltamivir-resistance, especially when this drug is used as monotherapy. Further clinical experience and trials will support or refute newer guidelines on the management of pandemic (H1N1) 2009 in such patients.